Since acquiring exclusive rights to launch and commercialise catumaxomab in 2024, in partnership with Lindis Biotech, Pharmanovia has been committed to ensuring people have access to a treatment that ...

The cellular therapy landscape continues to evolve beyond hematologic malignancies, now making significant progress in solid ...

Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today ...

In this study, researchers aimed to determine whether ctDNA is detectable in other bodily fluids besides blood, and to characterize any ctDNA they were able to detect.

Ghent, Belgium, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Sequana Medical announces execution of letter of intent to amend terms of the Kreos Loan Letter of intent to amend the loan from funds managed by ...

up to 261,895 new shares can be issued upon the exercise of 90,780 share options that are still outstanding under the 'Executive Share Options' plan for staff members and consultants of the Company, ...

Cogent Biosciences (COGT) shares have surged after pivotal bezuclastinib data in imatinib-resistant aGIST. Read the latest ...

New research shows that a high-fat diet causes cellular damage that directly paves the way for liver cancer. The strain comes ...

We present a case of a female in her late 40s with a 5-year history of well-managed type II diabetes mellitus, systemic hypertension and dyslipidaemia presented with acute severe abdominal pain, ...

The debate over Veterinary Professional Associates centers on expanding care access versus maintaining patient safety standards.

Large PBC cohort shows current liver stiffness measurement >10 kPa predicts hepatic decompensation, outperforming biochemical response or LSM trajectory. Learn more ...

Ghent, Belgium, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Transparency Notification from Shareholders PRESS RELEASE REGULATED INFORMATION ...